Squarepoint’s Krystal Biotech KRYS Stock Holding History

Squarepoint’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,800	Closed	-$874K	–	5291
2024 Q3	$874K	Buy	+4,800	New	+$926K	﹤0.01%	2704

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's KRYS Position: Q2 2026 in Review

Squarepoint sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,138 shares — an estimated $340K sold.

Squarepoint first reported a position in KRYS in Q4 2017 and held it in 16 quarters. The position peaked at $14.8M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Squarepoint reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 1,138 Krystal Biotech shares in Q2 2026, an estimated $340K.
Squarepoint first reported a position in Krystal Biotech in Q4 2017 and held it in 16 quarters.
Squarepoint's Krystal Biotech position peaked at $14.8M in Q1 2025.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.